Sectors
SLS
SELLAS Life Sciences Group, Inc.
4.11
7 x 3.16
13 x 5.33
bid
ask
-
0.25
5.84%
10:37 AM
timesize
Ytd 9.02%
1y 270.28%
4.12
day range
4.40
1.04
52 week range
5.96
Open 4.40 Prev Close 4.37 Low 4.12 High 4.40 Mkt Cap 739.88M
Vol 2.41M Avg Vol 8.84M EPS -0.25 P/E N/A Forward P/E -2.11
Beta 2.40 Short Ratio 14.07 Inst. Own 7.36% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 05-12 50-d Avg 4.55 200-d Avg 2.63 1yr Est 5.83
Earning
Date For Estimate Reported Surprise surprise %
2026-03-19 2025-12 0 N/A N/A N/A
2025-11-12 2025-09 0 N/A N/A N/A
2025-08-12 2025-06 0 N/A N/A N/A
2025-05-13 2025-03 0 N/A N/A N/A
2025-03-20 2024-12 0 N/A N/A N/A
2024-11-13 2024-09 0 N/A N/A N/A
Upgrade / Downgrade
Date Firm Action From To
2023-11-22 Cantor Fitzgerald Upgrade Overweight Overweight
2023-09-07 Cantor Fitzgerald Upgrade Overweight Overweight
2022-11-15 Alliance Global Partners Upgrade Buy
2022-06-28 Cantor Fitzgerald Upgrade Overweight
2021-07-21 Cantor Fitzgerald Upgrade Overweight
2019-11-15 Maxim Group Upgrade Hold Buy
Profile
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Insider Holder
Date Name Relation Quantity Description
2024-01-21 BURNS JOHN THOMAS Chief Financial Officer 101.93K Stock Award(Grant)
2024-01-21 FRANCOMANO ROBERT Officer 40.92K Stock Award(Grant)
2024-01-21 KALIN KATHERINE BACH Director 8.50K Stock Award(Grant)
2024-01-21 SCHEINBERG DAVID A Director 10.58K Stock Award(Grant)
2024-01-21 STERGIOU ANGELOS M Chief Executive Officer 376.42K Stock Award(Grant)
2024-01-21 VAN NOSTRAND ROBERT L Director 10.40K Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2024-09-29 Vanguard Group Inc 2.29M 2.08M 3.26%
2024-09-29 Anson Funds Management LP 793.84K 721.68K 1.13%
2024-09-29 Geode Capital Management, LLC 605.19K 550.18K 0.86%
2024-09-29 Blackrock Inc. 431.62K 392.38K 0.61%
2024-09-29 Opus Capital Group, LLC 226.10K 205.55K 0.32%
2024-09-29 State Street Corporation 174.53K 158.66K 0.25%
Fund Ownership
Report Date Organization Position Value Percentage
2024-09-29 Vanguard Total Stock Market Index Fund 1.69M 1.54M 2.40%
2024-09-29 Vanguard Extended Market Index Fund 501.97K 456.34K 0.71%
2024-10-30 Fidelity Extended Market Index Fund 311.43K 283.12K 0.44%
2024-10-30 iShares Micro Cap ETF 131.65K 119.68K 0.19%
2024-10-30 Fidelity Total Market Index Fund 119.19K 108.36K 0.17%
2024-10-30 Fidelity Series Total Market Index Fund 85.89K 78.08K 0.12%
Dividend
Dividend Date
0.42 2010-12-09
0.15 2010-09-09
Split
Split Date
1 : 50 2019-11-08
1 : 50 2019-11-06
1 : 30 2018-01-02
1 : 30 2018-01-01
1 : 20 2016-11-14